BridgeMD
FIRE Stones : Impact of Furosemide on the residual fragment rate after flexible ureteroscopy for destruction of kidney stones with laser : a controlled two-parallel group multicenter trial with blinding evaluation
EU CTIS ID: 2022-502890-40-00
What this study is testing
To show that the injection of 40 mg of Furosemide in slow intravenous during 10 minutes after the procedure, increases the stone-free rate 3 months after a flexible ureteroscopy for destruction of kidney stones with laser.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female ≥ 18 years old < 80 years old
- With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser
- Person affiliated to a French social security system or equivalent
- Written informed consent obtained from the participant
- Ability for participant to comply with the requirements of the study
- Stones of less than 3 cm
You likely can't join if
- Contra-indication to Furosemide: o Hyper-sensitivity to the active substance or one of the excipients o Hyper-sensitivity to Sulfonamide o Renal failure with oligo-anuria refractory to Furosemide o Hypokalemia < 3,5 mmol/L o Severe hyponatremia o Hypovolemia with or without hypotension or dehydration o Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy
- Patient having Furosemide as usual treatment
- Patient requiring an injection of Aminoside or Vancomycin before or during the procedure
- Participation in other interventional research with an investigational drug or medical device
- Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship)
- Hepatic insufficiency due to the risk of hepatic encephalopathy
See the full eligibility criteria
- Male or female ≥ 18 years old < 80 years old
- With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser
- Person affiliated to a French social security system or equivalent
- Written informed consent obtained from the participant
- Ability for participant to comply with the requirements of the study
- Stones of less than 3 cm
- Contra-indication to Furosemide: o Hyper-sensitivity to the active substance or one of the excipients o Hyper-sensitivity to Sulfonamide o Renal failure with oligo-anuria refractory to Furosemide o Hypokalemia < 3,5 mmol/L o Severe hyponatremia o Hypovolemia with or without hypotension or dehydration o Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy
- Patient having Furosemide as usual treatment
- Patient requiring an injection of Aminoside or Vancomycin before or during the procedure
- Participation in other interventional research with an investigational drug or medical device
- Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship)
- Hepatic insufficiency due to the risk of hepatic encephalopathy
- Hepatorenal syndrome
- Hypoproteinemia especially in case of nephrotic syndrome
- Drug-drug interactions with furosemide especially the lithium
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.